Adial Pharmaceuticals receives notice of allowance for new U.S. patent
Adial Pharmaceuticals announced on Thursday that it has received a Notice of Allowance for the issuance of a patent by the United States Patent and Trademark Office, entitled "Serotonin Transporter Gene and Treatment of Alcoholism." The Patent addresses a method of identifying and treating alcohol use disorder in patients with a specific genetic biomarker in the serotonin transporter gene. The methods include treating patients with an antagonist of the serotonin receptor after detection of the biomarker in the patient. The genetic biomarker is part of the genetic panel used to identify patients for inclusion in Adial's Phase 3 trial of AD04 for the treatment of AUD in genetically targeted patients. William Stilley, CEO of Adial Pharmaceuticals, commented, "This Notice of Allowance by the USPTO is another important milestone as we progress towards Adial's planned Phase 3 trial of AD04 and further solidifies the patent estate around AD04. We believe our growing global patent estate further illustrates that we have a novel drug for the treatment of alcohol use disorder, one of most pervasive and devastating diseases that exists today."